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Abstract: Alprazolam is effective as an anxiolytic and in the adjunct treatment of depression. In this study, 
the effects of calcium channel antagonists on the antidepressant action of alprazolam and imipramine were 
investigated. A forced swimming maze was used to study behavioral despair in albino mice. Mice were 
divided into nine groups (n = 7 per group). One group received a single dose of 1% Tween 80; two groups 
each received a single dose of the antidepressant alone (alprazolam or imipramine); two groups each 
received a single dose of the calcium channel blocker (nifedipine or verapamil); four groups each received a 
single dose of the calcium channel blocker followed by a single dose of the antidepressant (with same doses 
used for either in the previous four groups). Drug administration was performed concurrently on the nine 
groups. Our data confirmed the antidepressant action of alprazolam and imipramine. Both nifedipine and 
verapamil produced a significant antidepressant effect (delay the onset of immobility) when administered 
separately. Verapamil augmented the antidepressant effects of alprazolam and imipramine (additive 
antidepressant effect). This may be due to the possibility that verapamil might have antidepressant-like effect 
through different mechanism. Nifedipine and imipramine combined led to a delay in the onset of immobility 
greater than their single use but less than the sum of their independent administration. This may be due to the 
fact that nifedipine on its own might act as an antidepressant but blocks one imipramine mechanism that 
depends on L-type calcium channel activation. Combining nifedipine with alprazolam produced additional 
antidepressant effects, which indicates that they exert antidepressant effects through different mechanisms. 
 
Introduction 
Alprazolam is an anxiolytic agent used primarily 
for short-term relief of mild to moderate anxiety 
and nervous tension.  It is effective in the 
treatment of depression and panic attacks. It has a 
high affinity for the GABA benzodiazepine receptor 
complex [1], and it is a full agonist for the GABAA 
receptor [2]. Imipramine is a better tricyclic 
antidepressant than all other drugs in its category 
[3]. It prevents the reuptake of noradrenaline (NA) 
and 5-hydroxytryptamine (5-HT) at nerve terminals 
[4].  
Calcium antagonists have been shown to affect 
many different physiological processes, in 
particular neurotransmitter release. Nifedipine 
mainly affects the heart and smooth muscle, 
causing inhibition of calcium entry associated with 
depolarization. Nifedipine is relatively smooth 
muscle selective and acts as a vasodilator [1]. It is 
a highly specific antagonist of the L-type channel 
blocks [5]. Verapamil is relatively cardioselective 
with an antidysrhythmic action. Verapamil is 
effective in the treatment of hypertension and 
angina [1]. Verapamil enhanced the 
antidepressant action of alprazolam (6); Verapamil 
as an inhibitor of the CYP 450 3A4 (7) may affect 
the imipramine (8) and alprazolam action, that are 
considered as substrates for CYP 450 3A4 (7)  
The forced swim test (FST) [9] is used as a 
rodent model of depression. The mouse FST 
model has been widely used in screening 
antidepressants because it is simple and has been 
reported to be reliable across laboratories. The 
mouse model is more sensitive than the rat model 
because it produces fewer false positives [10]. The 
FST is specific enough to discriminate between 
antidepressants, neuroleptics and anxiolytics [11]. 
It is based on the observation that when an animal 
is forced to swim in a situation from which there is 
no escape, it will first go through a period of 
vigorous activity and then cease to move, other 
than trying to keep its head above water. 
Immobility indicates a state of despair in which the 
mouse has learned that escape is impossible. 
FST immobility is reduced by different 
treatments known to be effective in depression 
[12, 13]. There is a significant correlation between 
the potency of antidepressants in the FST and in 
clinical settings, but such a correlation has not 
been demonstrated in any other animal model of 
depression [12, 14].  In this model the circadian 
time cycle did not alter the duration of immobility 
of mice [15].  
Behavioral despair is mediated by central 
catecholamines. Drugs that increase central 
transmission of dopamine or NA decrease 
immobility, whereas agents having the opposite 
effect increase immobility. The advantage of the 
mouse FST  model  is that it can readily test the 
possible mechanisms of antidepressant action by 
using specific agonists/antagonists. By 
augmenting or blocking antidepressant activity 
with agonist/antagonist receptor ligands, it is 
possible to detect which receptor is involved in the 
antidepressant effect [16].  
In this study we used behavior despair models 
for mental depression to investigate the effect of 
the calcium channel blockers, nifedipine and 
verapamil, on the antidepressant action of 
alprazolam and imipramine. These two calcium 
channel blockers are used in the treatment of 
physical illnesses that may be concurrent with 
depression. Understanding the interaction 
between antidepressants and calcium channel 
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blockers could indicate whether there is a need to 
modify antidepressant doses when coadministered 
with calcium channel blockers.  
 
Materials and methods 
Albino mice (25 - 40 g) were used. Groups of 
mice were housed in separate cages. The animals 
were housed at room temperature (20–25°C) and 
a 12-h dark/light cycle. Alprazolam was supplied 
by Upjohn Co. Ltd, Egypt, Imipramine by Novartis, 
AG, Switzerland, Nifedipine by Bayer, AG, 
Germany, and Verapamil by Weimer Phara Gmbh, 
Germany. 
Because alprazolam is not freely soluble in 
saline, all the drugs were dissolved in 1% Tween 
80 in distilled water [17]; they were injected 
intraperitoneally. Imipramine was given at 10 
mg/kg and alprazolam at 5 mg/kg [18 and our 
unpublished results]. The doses of calcium 
channel blockers were chosen from previous 
studies [18-21].  
Mice were divided into nine groups (n = 7 per 
group). One group received a single dose of 
5ml/kg of 1% Tween 80; two groups each received 
a single dose of the antidepressant alone 
(alprazolam, 5mg/kg; imipramine, 10mg/kg); two 
groups each received a single dose of the calcium 
channel blocker (nifedipine, 5mg/kg; verapamil, 
10mg/kg); four groups each received a single dose 
of the calcium channel blocker followed by a single 
dose of the antidepressant (with same doses used 
for either in the previous four groups). Drug 
administration was performed concurrently on the 
nine groups. For all groups, the time of onset of 
immobility was measured 60 min after drug 
administration.  
We used a behavioral model of immobility first 
postulated by Porsolt [22] and Porsolt et al. and 
named the behavioral despair model [23]. In this 
model, mice are forced to swim in a restricted 
space from which there is no escape. Following an 
initial period of vigorous activity, the mice adopt a 
characteristic immobile posture with no further 
attempt to escape, and this reflects a state of 
despair or lowered mood. Mice were forced to 
swim for four minutes in a vertical glass cylinder 
(height=27 cm, diameter=16.5 cm) containing 
fresh tap water at 27°C and a depth of 15 cm [24]. 
Mice were forced to swim only once. 
 
Statistical analysis 
SPSS 8 software was used to determine 
whether the observed data were normally 
distributed using Kolmogrov Smirnov maximum 
deviation test for goodness of fit. If the data were 
normally distributed, one-way ANOVA was 
applied, followed by Post Hoc test to compare 
between groups. If the data were not normally 
distributed, groups were compared using Mann-
Whitney two samples (non–matched) U test. The 
difference was considered to be significant at p ≤ 
0.05. 
 
Results 
Effects of nifedipine on the onset of immobility 
Administration of imipramine, alprazolam, or 
nifedipine separately produced a significant delay 
in the onset of immobility compared to the control 
group. The combined administration of alprazolam 
and nifedipine produced a significant delay in the 
onset of immobility compared to either alprazolam 
treated mice or the control group. The effect of 
imipramine on the onset of immobility (delay) was 
potentiated by the administration of nifedipine 
(Table 1). 
Table 1: Effects of nifedipine on the onset of immobility by 
alprazolam and imipramine using the behavior despair model 
of depression. The values are expressed as mean ± S.E.M. a: 
p  ≤ 0.05 compared to control group treated with Tween 80-
treated. b: p ≤ 0.05 compared to group treated with alprazolam 
+ nifedipine. c: p ≤ 0.05  compared to group treated with 
imipramine + nifedipine. 
Treatment (n = 7)  Onset of 
immobility (sec) 
Tween 80  40.5 ± 0.99 
Alprazolam 
(5 mg/kg) 
59.8 ± 1.16 
a, b 
Alprazolam (5mg/kg) + 
Nifedipine (5 mg/kg) 
72.1 ± 1.18 
a 
Imipramine 
(10 mg/kg) 
77.1 ± 0.83 
a,  c 
Imipramine (10 mg/kg) + 
Nifedipine (5 mg/kg) 
83.4 ± 1.04 
a 
Nifedipine (5 mg/kg)  60.1 ± 1.48 
a, b,  c 
 
Effects of verapamil on the onset of immobility 
Administration of verapamil, alprazolam or 
imipramine produced a significant delay in the 
onset of immobility compared to the control group. 
Coadministration of verapamil augmented the 
effects of imipramine. Similarly, coadministration 
of verapamil augmented the effects of alprazolam. 
Our findings demonstrate that verapamil 
significantly delays the onset of immobility 
produced by alprazolam (Table 2).  
 
Discussion  
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It has been suggested that calcium channel 
inhibitors may have antidepressant properties, and 
that calcium may play an important role in affective 
disorders [25]. Voltage-dependent calcium channel 
antagonists have been reported to produce 
antidepressant-like effects in rodents [26-28]. 
Interruption of the Ca
2+-calmodulin-NOS-guanylyl 
cyclase subcellular signaling pathway at any point 
produces antidepressant-like effects [26].  
Table 2:  Effects of verapamil on the onset of immobility 
produced by alprazolam or imipramine using the behavior 
despair model of depression. The values are expressed as 
mean ± S.E.M. a: p ≤ 0.05 compared to control group treated 
with Tween 80-treated. b: p ≤ 0.05 compared to group treated 
with alprazolam + verapamil. c: p ≤ 0.05  compared to the 
group treated with imipramine + verapamil. 
Treatment (n = 7)  Onset of immobility (sec) 
Tween 80  40.5 ± 0.99 
Alprazolam 
(5 mg/kg) 
59.8 ± 1.16 
a, b  
Alprazolam (5 
mg/kg)+ Verapamil 
(10 mg/kg) 
82.8 ± 0.73 
a 
Imipramine 
(10 mg/kg) 
77.1 ± 0.83 
a,  c 
Imipramine (10 
mg/kg) +Verapamil 
(10 mg/kg) 
93.5 ± 1.13 
a 
Verapamil 
(10 mg/Kg) 
57.4 ± 0.61 
a, b, c 
 
In our study, nifedipine delayed the onset of 
immobility in the forced swimming maze. This 
antidepressant action could have been mediated 
by 5-HT1A activation [29], whereby nifedipine 
reduced 5-HT uptake [30].  This would lead to an 
increase in the cytosolic calcium activity via 5-HT2 
receptors [31]. Serotonin may activate calcium 
influx through calcium channels by activation of 5-
HT receptors, which are insensitive to nifedipine 
[32], in neuronal cells. The increase in calcium 
influx is through 5-HT3 receptors [31, 33], the 5-
HT3 receptor being a ligand-gated ion channel 
activated by the neurotransmitter serotonin. 
Receptors of this subtype have been localized to 
several regions of the brain, they appear to be 
involved in many neuronal functions [34], and to 
mediate antidepressant effects [35].  In glial cells, 
the increase in intracellular calcium is through 5-
HT2 receptors [31]. It has been suggested that the 
pharmacology of L-type Ca
2+-channel blockers 
overlaps with that of 5-HT2 receptor antagonists 
[36].  
Nifedipine may produce an antidepressant 
action through GABAA activation [37], which leads 
to the release of NA that produces an 
antidepressant effect [38]. This may be GABA 
acting on second inhibitory interneurons (as in 
direct and indirect pathways of extrapyramidal 
systems). Nifedipine may also produce its 
antidepressant effect by increasing the release of 
intracellular calcium through GABAA receptors 
[37] and NA [39, 40]. The central antidepressant 
effect of nifedipine may be mediated through an 
interaction, with novel modulatory sites on GABAA 
receptors, that is not through picrotoxin, flumazenil 
or Zn
+2 sites [37].   
Nifedipine may exert an antidepressant action 
by decreasing the ability of vesicles to re-uptake 
NA [41]. Nifedipine may block calcium uptake 
through potential operated (K
+) channels or 
through receptor operated (5-HT) channels [42]. 
Moreover, verapamil showed an antidepressant-
like effect as it delayed the onset of immobility in 
the swimming maze. Studies have shown that 
verapamil modulates the action of antidepressant 
drugs that downregulate β adrenergic systems 
[43]. It has a similar final effect as β blockers, and 
shares this effect with antidepressant drugs [44]. 
Working on different types of calcium entry, 
verapamil blocks the prejunctional α2 receptors, 
which leads to an increase in NA release [45-48]. 
Verapamil may have direct catecholamine-
releasing effects, as it interacts with 
catecholamine storage vesicles in a way that 
reduces their ability to take up and store 
catecholamine, and thereby   increasing NA 
release from sympathetic nerves [41]. Verapamil 
has no effect on NA-induced increase in calcium 
influx, which means that there are verapamil-
sensitive and verapamil-insensitive calcium 
channels [49]. Verapamil enhances ATP response 
[50], which is released along with NA from the 
motor nerves; ATP may indeed be a co-transmitter 
[51, 52]. Allgaier et al. suggested that ATP 
induces NA release from sympathetic neurons via 
its action on a subclass of the nicotinic 
cholinoceptor, because this effect was blocked by 
nicotinic receptor antagonists [53]. NA produces 
depolarization by decreasing the membrane 
permeability to K
+ ions. It also increases calcium 
influx to the cells via calcium channel-activated NA 
receptors and potential-dependent slow calcium-
channels activated by NA-induced membrane 
depolarization [54]. NA stimulates calcium chloride 
conductance, leading to opening of voltage-gated 
calcium channels [55].  
Verapamil inhibits 5-HT uptake by a mechanism 
that does not involve alteration in calcium fluxes 
(56), which leads to enhancement of 5-HT release 
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[57]; verapamil produces competitive inhibition of a 
5-HT carrier and inhibits Na
+-dependent uptake of 
5-HT [58, 59], which is competitively inhibited by 
imipramine [59]. It also facilitates the release of 
large amounts of K
+-induced 5-HT in the 
hippocampus synaptosomatic sites. The release is 
dose dependent and mediated by presynaptic 
receptors.  This increase in endogenous 5-HT is 
independent of the presence of external calcium 
[60]. Serotonin activates 5-HT1A receptors to 
produce an antidepressant effect [61].  It also 
activates 5-HT3 presynaptic receptors, inducing 
calcium influx [62, 63], which triggers the release 
of calcium from intracellular stores and leads to 
increased calcium in both the cytoplasm and 
nucleus [63]. Activating 5-HT3 postsynaptic 
receptors induces depolarization [62]. Thus both 
mechanisms would result in an antidepressant 
action.  
Serotonin may regulate GABA 
neurotransmission through 5-HT3 receptors [64]. It 
also increases chloride channel activity by acting 
on the 5-HT1C receptor [65, 66]. It has been 
suggested that
  the increased [Ca
2+]i activates 
chloride channels (Cl), causing
 an efflux of chloride 
and subsequent depolarization of the cell
 
membrane; this leads to the opening of voltage-
gated calcium channels
  [67,68]. Cl
- currents can 
be activated separately by Ca
2+ release from 
intracellular stores (in response to external 
application of caffeine or NA) and by Ca
2+ influx 
through voltage-dependent Ca
2+ channels [69]. 
Activation of Cl- channels by Ca
2+ release 
produces a membrane depolarization that is 
required for an enhanced opening of voltage-
dependent Ca
2+ channels in response to 
noradrenaline in venous smooth muscle [70]. It 
was concluded
  that extracellular chloride is 
essential for contraction in afferent
 arterioles after 
activation of voltage-dependent calcium channels 
[71]. 
Verapamil cannot modify calcium-dependent 
fractions of GABA release induced by high K
+ 
depolarization [72]. Presynaptic action of Zn in the 
hippocampus increases the release of GABA in 
the synaptic cleft. This Zn effect is not affected by 
verapamil. Zinc enhances GABA release by 
potentiating AMPA/Kaiate receptors in the 
hippocampus region, followed by a decrease in 
presynaptic glutamate release. Zinc is considered 
an inhibitory neuromodulator of glutamate [73]. 
The NMDA receptor gates two inhibitory sites for 
zinc, one is voltage dependent (74) and the other 
is not (74-76). The γ-amino butyric acid released 
from striatal slices is calcium-independent. 
Calcium channels may play two roles in the 
regulation of depolarization-induced GABA 
release. First, they permit depolarization-induced 
influx of calcium, which then promotes GABA 
release. Second, they influence GABA release 
through a mechanism that does not involve 
external calcium. It has been proposed that 
calcium channels serve to permit an influx of Na
+, 
which in turn promotes calcium-independent 
GABA release through an influence on the high 
affinity GABA transport system [77]. Blockage of 
choline uptake may play a role in the 
antidepressant-like effect of verapamil [78].   
Alprazolam may produce antidepressant effects 
independently of benzodiazepine receptors, 
through the GABA–ergic mechanism.  Flumazenil 
did not antagonize the antidepressant effects of 
alprazolam or imipramine, while these effects 
were blocked by picrotoxin [79]. Enhanced 5-HT 
release in the hippocampus, exhibited by the 
atypical benzodiazepine, alprazolam, but not by 
the typical benzodiazepine, diazepam, may 
underlie the antidepressant activity of alprazolam 
[80]. It has been suggested that some of the 
neuronal stabilizing effects of benzodiazepine 
receptors may be mediated by the regulation of 
Ca
2+ conductance, as benzodiazepine binding 
sites regulate voltage-sensitive Ca
2+  channels in 
brain membranes [81]. Benzodiazepines and 
calcium channel inhibitors cause significant 
inhibition of adenosine transport; hence, this 
potentiates adenosine action at the concentration 
required to induce effects through occupation of 
their respective, specific high-affinity sites [82]. 
Benzodiazepine (clonazepam, flunitrazepam, and 
diazepam) binding sites regulate voltage-sensitive 
Ca
2+  channels in brain membranes, and it has 
been suggested that some of the neuronal 
stabilizing effects of benzodiazepine receptors 
may be mediated by the regulation of Ca
2+ 
conductance [81]. Diazepam had no effect on the 
immobility time in the swimming maze, but 
antagonized the antidepressant effect of 
imipramine [83]. This means that both alprazolam 
and imipramine produce antidepressant effects 
through voltage-sensitive Ca
2+  channels. 
Benzodiazepines act as Ca
2+-channel antagonists 
[84]; this antagonism may not be related to their 
antidepressant action [85, 86]. 
Imipramine can inhibit presynaptic reuptake of 
the biogenic amines, serotonin, and NA to 
produce an antidepressant action [87-89]. 
Imipramine may produce this antidepressant 
action through a GABA–ergic mechanism, causing 
release of catecholamines [79]. Imipramine may 
increase calcium release from intracellular stores 
[90] by increasing NA concentrations through 
inhibiting its uptake by pre-synaptic sites [87], 
through GABAA receptor activation.  This may 
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lead to increased calcium influx through voltage-
gated calcium channels, which ultimately depend 
on the chloride transport system [91], or by 
depolarization due to an increase in the external 
potassium concentrations. It was suspected that 
this might lead to calcium influx through voltage 
activated calcium channels [92]. However, 
nifedipine does not affect calcium channel 
mediation of initial response to NA [93]. Nifedipine 
blocks L-type calcium channels activation which is 
due GABAA receptor activation-mediated 
depolarization [94, 95], which may not play a role 
in the antidepressant action.  GABAA receptor 
activation increases the release of calcium from 
the internal stores [95]. Imipramine produces an 
inhibition of the peak threshold calcium current, 
which probably decreases the maximum available 
calcium conductance [96]. It was suggested that 
imipramine acts by interfering with the influx of 
extracellular calcium, through both the receptor-
operated and voltage-gated calcium channels, but 
does not affect the release of calcium from 
intracellular storage sites [97, 98].  
In the present study we showed that verapamil 
has an antidepressant-like effect in the mouse 
swimming maze model. Treatment with verapamil 
combined with alprazolam or imipramine produces 
an additive antidepressant effect, possibly 
because verapamil has an antidepressant-like 
effect, but the mechanism is not understood yet.  
Either imipramine or nifedipine produced a delay 
in the onset of immobility of 75% and 81%, 
respectively, compared to the control. Combining 
nifedipine with imipramine led to a delay of 73% in 
the onset of immobility compared to the control; 
which is less than the additive effect. This 
observation could be explained by the fact that 
nifedipine has its own antidepressant action 
mechanism but also blocks the imipramine 
mechanism that depends on L-type calcium 
channel activation. 
This study showed that nifedipine possesses 
antidepressant properties. Combining nifedipine 
with alprazolam produced an additive 
antidepressant effect, indicating that different 
mechanisms were involved.  
 
References 
1. Rang MM, Dale JM, Ritter. Pharmacology. CNS stimulants 
and psychomimetic drugs 1996; Third edition. Laurence Hunter, 
New York, London.  Chapter four, P:634. 
2. Hascoet M, Bourin M. Anti-conflict effect of alpidem as 
compared with the benzodiazepine alprazolam in rats. 
Pharmacol. Biochem. Behav. 1997;56(2): 317 – 324. 
3. Reynolds JEF, Partitti K, Parson AV, Sweetman SC. The 
imipiramine. In: Martindale. The extra pharmacopeia. Royal 
pharmaceutical society.  1996; Thirty-first edition, 316– 317. 
4. Baldessarini JR. Drugs and treatment of psychiatric 
disorders (depression and mania). In: Goodman and Gilman’s 
The Pharmacological Basis of Therapeutics1996; 9
th edition. 
McGraw-Hill, New York. Chapter 19, p 431.  
5. Pin JP, Bockaert J. Omega-conotoxin GVIA and 
dihydropyridines discriminate two types of Ca2+ channels 
involved in GABA release from striatal neurons in culture. Eur 
J. Pharmacol. 1990; 188: 81-84. 
6. Kozlovskiĭ VL, Prakh'e IV. The influence of calcium 
channel blockers on antidepressant effects Eksp Klin 
Farmakol. 1996;  59(5): 9-11. 
7. Mathys M. Drug Interactions Associated with the Use of 
Antidepressant Medications. Internet Continuing Education 
2005; 9:(3) 1-15. 
8. Spina E, Scordo MG. Clinically significant drug 
interactions with antidepressants in the elderly. Drugs Aging 
2002;19(4):299-320. 
9. Porsolt RD, Lepichon M, Jalfra M. Depression: a new 
animal model sensitive to antidepressant treatments. Nature 
1977; 266:730-732. 
10. Porsolt RD, and Lenegre A. Behavioural models of 
depression. Experimental approaches to anxiety and 
depression 1992; 5:73-84. 
11. Borsini F, Meli A. Is the forced swimming test a suitable 
model for revealing antidepressant activity? 
Psychopharmacology 1988; 94: 147-160. 
12. Cryan JF, Markou A, Lucki I. Assessing antidepressant 
activity in rodents: recent development and future needs. 
Trends in Pharmacological Sciences 2002; 23(5): 238-245. 
13. Jaanus H. Animal Models for Better Antidepressants: 
Can Pathogenetic Approaches Make a Difference? Review 
2004; 2(6): 402-407. 
14. Willner P. The validity of the animal models of 
depression. Psychopharmacology 1984; 83:1-16. 
15. Raghavendra V, Kaur G, Kulkarni SK. Anti-depressant 
action of melatonin in chronic forced swimming-induced 
behavioral despair in mice, role of peripheral benzodiazepine 
receptor modulation. Eur Neuropsychopharmacol 2000; 
10(6):473-481. 
16. Bourin M, Fiocco AJ, Clenet F. How valuable are animal 
models in defining antidepressant activity? Hum. 
Psychopharmacol. Clin. Exp. 2001; 16:9-14. 
17. Collinge J, Pycock CJ, Taberner PV. Studies, on the 
interaction between cerebral 5- Hydroxy tryptamine and 6-
amino butyric acid in the mode of action of Diazepam in the rat.  
Br. J. Pharmac 1983; 79:637–643.        
18. Biala G. Antidepressant-like properties of some 
serotonin receptor ligands and calcium channel antagonists 
measured with the forced swimming test in mice. Polish 
Journal of Pharmacology. 1998; 50(2):117-124.  
19. Ali A, Pillai KK, Pal SN, Ahmad FJ, Vohora D. Addition of 
folic acid to phenytoin ameliorates neuropharmacological 
complications in mice. Asia Pacific Journal of Pharmacology. 
2004; 16(2):83-88. 
20. Szymczyk G, Zebrowska-Lupina I. Influence of 
antiepileptics on efficacy of antidepressant drugs in forced 
swimming test. Polish Journal of Pharmacology. 2000; 
52(5):337-344. 
21. Volterra G, Lecci A. Interaction of antidepressants with 
4-aminopyridine. Life Sciences. 1992; 51(6):PL53-PL56 
22. Porsolt RD. Behavioral despair. In: neurochemical., 
behavioral and clinical perspespective. (edit: Enna, S.J.; 
Malick, J. P., Richelson, e.). Reven Press, New York  1981; 
121–139. 
23. Porsolt RD, Bertin A, Jalfer M. Behavioral despair in rats 
and mice: Strain differences and the effect of imipramine. Eur. 
Pharmacol 1978; 51:291-294. 
24. Abel EL. A further analysis of physiological changes in 
rats in the forced swim test. Physiol Behav 1994; 56(4):795-
800. 
25. Helmeste DM, Tang SW. The role of calcium in the 
etiology of the affective disorders. Japanese Journal of 
Pharmacology 1998; 77(2):107-116.  
Page 173   
Original Article   
www.ljm.org.ly
 
 
 
  Libyan J Med, AOP: 070909
 
26. Paul IA. Antidepressant activity and calcium signaling 
cascades. Human Psychopharmacology 2001; 16(1):71-80  
27. Rehavi M, Carmi R, Weizman A. Tricyclic 
antidepressants and calcium channel blockers: Interactions at 
the (-)-desmethoxyverapamil binding site and the serotonin 
transporter. Eur. J. Phamacol. 1988; 155(1-2):1-9.  
28. Geoffroy M, Mogilnicka E, Nielsen M, Rafaelsen OJ. 
Effect of nifedipine on the shuttlebox escape deficit induced by 
inescapable shock in the rat. Eur. J. Phamacol. 1988; 
154(3):277-283.  
29. Bayliss DA, Umemiya M, Berger AJ. Inhibition of N- and 
P-type calcium currents and the after-hyperpolarization in rat 
motoneurons by serotonin. J Physiol 1995; 485(3):635–647.  
30. Ladewig T, Lalley PM, Keller BU. Serotonergic 
modulation of intracellular calcium dynamics in neonatal 
hypoglossal motoneurons from mouse. Brain Res. 2004; 
1001(1-2):1-12 
31. Reiser G, Donie F, Binmoller FJ. Serotonin regulates 
cytosolic Ca2+ activity and membrane potential in a neuronal 
and in a glial cell line via 5-HT3 and 5-HT2 receptors by 
different mechanisms. J. Cell Sci. 1989; 93(Pt 3):545-555 
32. Buryi VA, Gurkovskaia AV, Gokina NI, Shuba MF. Effects 
of the membrane potential level on serotonin-induced 
contraction of the pulmonary artery smooth muscle in rabbits. 
Biull. Eksp. Biol. Med. 1992; 113(1):13-16 
33. Linhart O, Obreja O, Kress M. The inflammatory 
mediators serotonin, prostaglandin E2 and bradykinin evoke 
calcium influx in rat sensory neurons. Neuroscience 2003; 
118(1):69-74. 
34. Lovinger DM. 5-HT3 receptors and the neural actions of 
alcohols: an increasingly exciting topic. Neurochem. Int. 1999; 
35(2):125-130 
35. Rammes G, Rupprecht R, Ferrari U, Zieglgansberger W, 
Parsons CG. The N-methyl-D-aspartate receptor channel 
blockers memantine, MRZ 2/579 and other amino-alkyl-
cyclohexanes antagonise 5-HT(3) receptor currents in cultured 
HEK-293 and N1E-115 cell systems in a non-competitive 
manner. Neurosci. Lett 2001; 306(1-2):81-84. 
36. Okoro EO. Overlap in the Pharmacology of L-type Ca
2+-
channel Blockers and 5-HT2 Receptor Antagonists in Rat Aorta. 
Journal of Pharmacy and Pharmacology 1999; 51(8):953-957. 
37. Das P, Bell-Horner CL, Huang RQ, Raut A, Gonzales 
EB, Chen ZL, et al. Inhibition of type A GABA receptors by L-
type calcium channel blockers. Neuroscience 2004; 
124(1):195-206 
38. Kataoka Y, Ohara-Imaizumi M, Ueki S, Kumakura K. 
Stimulatory action of gamma-aminobutyric acid on 
catecholamine secretion from bovine adrenal chromaffin cells 
measured by a real-time monitoring system. J. Neurochem 
1988; 50(6):1765-1768 
39. Leppert J, Nilsson H, Myrdal U, Edvinsson L, Hedner T, 
Ringqvist I. Sympathetic activation after two weeks of nifedipine 
treatment in primary Raynaud's patients and controls. 
Cardiovasc. Drugs Ther 1993; 7(6):901-907 
40. Khoyi MA, Dalziel HH, Zhang L, Bjur RA, Gerthoffer WT, 
Buxton IL, et al. [Ca2+]i-sensitive, IP3-independent Ca2+ influx 
in smooth muscle of rat vas deferens revealed by procaine. Br. 
J. Pharmacol. 1993; 110(4):1353-1358  
41. Terland O. Catecholamine release--unpredictable side 
effects of calcium antagonists. Tidsskr Nor Laegeforen 1992; 
112(15):1952-1954 
42. Wendling WW, Harakal C. Effects of calcium antagonists 
on isolated bovine cerebral arteries: inhibition of constriction 
and calcium-45 uptake induced by potassium or serotonin. 
Stroke 1987; 18(3):591-598 
43. Nalepa I, Kowalska M, Kreiner G, Vetulani J. Does Ca2+ 
channel blockade modulate the antidepressant-induced 
changes in mechanisms of adrenergic transduction? J. Neural. 
Transm. 1997; 104(4-5):535-547 
44. Hoste AM, Sys SU. The relaxant action of betaxolol on 
isolated bovine retinal microarteries. Curr. Eye Res. 1994; 
13(7):483-487 
45. Andersson KE.  Pharmacodynamic profiles of different 
calcium channel blockers. Acta. Pharmacol. Toxicol. 1986; 
58(2):31-42 
46. Galzin AM, Langer SZ. Presynaptic alpha 2-
adrenoceptor antagonism by verapamil but not by diltiazem in 
rabbit hypothalamic slices. Br. J. Pharmacol. 1983; 78(3):571-
577 
47. Turovaya AY, Galenko-Yaroshevskii PA, Kade,AKh, 
Uvarov AE, Kiguradze MI, Khvitiya NG, et al. Effects of 
verapamil and amiodarone on sympathoadrenal system and 
balance of excitatory and inhibitory amino acids in rat medulla 
oblongata. Bull. Exp. Biol. Med. 2005; 139(6):665-667 
48. Kudrin VS, Klodt PM, Gulieva ST. Neuropharmacological 
study of the joint action of verapamil and olanzapine on the 
content of neurotransmitters in Wistar rat brain structures. 
Eksp. Klin. Farmakol. 2005; 68(6):12-14 
49. Oriowo MA. Differential effect of verapamil on 
noradrenaline, carbachol, tyramine and 5-hydroxytryptamine 
induced contractions of the rat anococcygeus muscle. Arch. 
Int. Pharmacodyn. Ther. 1982; 259(2):186-93 
50. Raviprakash V, Mishra SK, Panda JN. Effect of 
verapamil on the non-adrenergic response of the field 
stimulated rat vas deferens. Naunyn. Schmiedebergs. Arch. 
Pharmacol. 1985; 331(4):347-350 
51. French AM, Scott NC. Evidence to support the 
hypothesis that ATP is a co-transmitter in rat vas deferens. 
Experientia. 1983; 39(3):264-266 
52. Garner C, Feniuk W, Brown PD. Serotonin activates Cl- 
channels in the apical membrane of rat choroid plexus 
epithelial cells. Eur. J. Pharmacol. 1993; 239(1-3):31-37. 
53. Clemens  Allgaier, Henning  Wellmann, 
Angelika Schobert,  Gerhart Kurz  and  Ivar von Kügelgen. 
Cultured chick sympathetic neurons: ATP-induced 
noradrenaline release and its blockade by nicotinic receptor 
antagonists. Naunyn-Schmiedeberg's Archives of 
Pharmacology 1995; 352(1):25-30.  
54. Gurkovskaia AV. Effect of manganese and verapamil on 
electrical and contractile responses of pulmonary artery 
smooth muscle induced by noradrenaline and histamine. Biull. 
Eksp. Biol. Med 1981; 92(8):7-9 
55. Criddle DN, de-Moura RS, Greenwood IA, Large WA. 
Effect of niflumic acid on noradrenaline-induced contractions of 
the rat aorta. Br. J. Pharmacol. 1996; 118(4):1065-1071 
56. Hill NS, Lee SL, Fanburg BL. Effect of calcium channel 
blockers on serotonin uptake. Proc. Soc. Exp. Biol. Med 1990; 
193(4):326-330 
57. Pietraszek M, Chabielska E, Malinowska B, Buczko W. 
The effect of verapamil on serotonergic mechanisms in the rat 
blood platelets. Pol. J. Pharmacol. Pharm. 1988; 40(1):81-86 
58. Lee SL, Long K, Ueda S, Fanburg BL. Verapamil inhibits 
serotonin uptake of endothelial cells in culture by a mechanism 
unrelated to Ca2+ channel blockade. J. Cell. Physiol. 1987; 
132(1):178-182 
59. Brown NL, Sirugue O, Worcel M. The effects of some 
slow channel blocking drugs on high affinity serotonin uptake 
by rat brain synaptosomes. Eur. J. Pharmacol. 1986; 
123(1):161-165 
60. Sitges M, Reyes A. Effects of verapamil on the release 
of different neurotransmitters. J. Neurosci. Res. 1995; 
40(5):613-621 
61. Biala G. Antidepressant-like properties of some 
serotonin receptor ligands and calcium channel antagonists 
measured with the forced swimming test in mice. Pol. J. 
Pharmacol. 1998; 50(2):117-124. 
62. Ronde P, Nichols RA. High calcium permeability of 
serotonin 5-HT3 receptors on presynaptic nerve terminals from 
rat striatum. J. Neurochem. 1998; 70(3):1094-1103. 
63. Ronde P, Nichols RA. 5-HT3 receptors induce rises in 
cytosolic and nuclear calcium in NG108-15 cells via calcium-
induced calcium release. Cell Calcium 1997; 22(5):357-365. 
Page 174   
Original Article   
www.ljm.org.ly
 
 
 
  Libyan J Med, AOP: 070909
 
64. Morales M, Bloom FE. The 5-HT3 receptor is present in 
different subpopulations of GABAergic neurons in the rat 
telencephalon. J. Neurosci. 1997; 17(9):3157-3167. 
65. Garner C, Feniuk W, Brown PD. Serotonin activates Cl- 
channels in the apical membrane of rat choroid plexus epithelial 
cell. Eur. J. Pharmacol. 1993;  239(1-3):31-37. 
66. Declan WA, Stefano C, Pierre D. Ionotropic and 
metabotropic activation of a neuronal chloride channel by 
serotonin and dopamine in the leech Hirudo medicinalis. The 
Journal of Physiology 1998; 509(1):211-219. 
67. Carmines PK. Segment-specific effect of chloride 
channel blockade on rat renal arteriolar contractile responses to 
angiotensin II. Am J Hypertens 1995; 8:90–94. 
68. Takenaka T, Kanno Y, Kitamura Y, Hayashi K, Suzuki H, 
and Saruta T. Role of chloride channels in afferent arteriolar 
constriction. Kidney Int. 1996; 50:864–872 
69. Baron A, Pacaud P, Loirand G, Mironneau C, Mironneau 
J. Pharmacological block of Ca(2+)-activated Cl- current in rat 
vascular smooth muscle cells in short-term primary culture. 
Pflugers Arch. 1991; 419(6):553-558. 
70. Pacaud P, Loirand G, Baron A, Mironneau C, Mironneau 
J. Ca2+ channel activation and membrane depolarization 
mediated by Cl- channels in response to noradrenaline in 
vascular myocytes. Br. J. Pharmacol. 1991; 104(4):1000-1006. 
71. Jensen BL, Ellekvist P, Skott O. Chloride is essential for 
contraction of afferent arterioles after agonists and potassium. 
Am J Physiol Renal Physiol 1997; 272:F389-F396. 
72. Sitges M, Chiu LM, Ramon de la Fuente J. The effect of 
verapamil on GABA and dopamine release does not involve 
voltage-sensitive calcium channels. Brain Res. 1990; 534(1-
2):51-59 
73. Takeda A, Minami A, Seki Y, Oku N. Differential effects 
of zinc on glutamatergic and GABAergic neurotransmitter 
systems in the hippocampus. J. Neurosci. Res. 2004; 
75(2):225-229 
74. Christine CW, Choi DW. Effect of zinc on NMDA 
receptor-mediated channel currents in cortical neurons. J. 
Neurosci. 1990; 10:108-116 
75. Peters S, Koh J, Choi DW. Zinc selectively blocks the 
action of N-methyl-D-aspartate on cortical neurons. Science 
1987; 236:589-593 
76. Westbrook GL, Mayer ML. Micromolar concentrations of 
Zn2+ antagonize NMDA and GABA responses of hippocampal 
neurons. Nature1987; 328:640-643 
77. Bernath S, Zigmond MJ. Calcium-independent GABA 
release from striatal slices: the role of calcium channels. 
Neuroscience 1990; 36(3):677-682 
78.  Bidzinski A, Jankowska E, Pucilowski O. 
Antidepressant-like action of nicardipine, verapamil and 
hemicholinium-3 injected into the anterior hypothalamus in the 
rat forced swim test. Pharmacol. Biochem. Behav. 1990; 
36(4):795-798 
79. Aburawi SM, Al-Tubuly RA, Ahmed SS, lghzewi EA, 
Gorash ZM. Effect of Flumazenil and Picrotoxin on 
antidepressant action of Alprazolam and Imipramine in albino 
mice using behavior despair. Fifth National Pharmaceutical 
Sciences Conference, Benghazi-Libya; 22-24 April 2005. 
80. Broderick PA. Alprazolam, diazepam, yohimbine, 
clonidine: in vivo CA1 hippocampal norepinephrine and 
serotonin release profiles under chloral hydrate anesthesia. 
Prog. Neuropsychopharmacol. Biol. Psychiatry. 1997; 
21(7):1117-1140 
81. Taft WC, DeLorenzo RJ. Micromolar-affinity 
benzodiazepine receptors regulate voltage-sensitive calcium 
channels in nerve terminal preparations. Proceedings of the 
National Academy of Sciences of the United States of America 
1984; 81/10I:3118-3122.   
82. Hammond JR, Williams EF, Clanachan AS. Affinity of 
calcium channel inhibitors, benzodiazepines, and other 
vasoactive compounds for the nucleoside transport system. 
Can. J. Physiol. Pharmacol. 1985; 63(10): 1302-1307.   
83. Biala G. Antidepressant-like properties of some 
serotonin receptor ligands and calcium channel antagonists 
measured with the forced swimming test in mice. Polish 
Journal of Pharmacology 1998; 50(2):117-124. 
84. Johansen J, Taft W C, Yang J, Kleinhaus A L, 
DeLorenzo RJ.  Inhibition of Ca2+ conductance in identified 
leech neurons by benzodiazepines. Proc Natl Acad Sci. 1985; 
82(11):3935–3939 
85. Molina-Hernández M, Tellez-Alcántara NP, Pérez García 
J, Olivera Lopez JI, Teresa Jaramillo M. Anxiolytic-like actions 
of leaves of Casimiroa edulis (Rutaceae) in male Wistar rats. 
Journal of Ethnopharmacology 2004; 93(1):93-98.  
86. Wieland S, Lucki I. Antidepressant-like activity of 5-
HT1A agonists measured with the forced swim test. 
Psychopharmacology 1990; 101(4):497-504. 
87. Sindrup SH, Otto M, Finnerup NB, Jensen TS. 
Antidepressants in the treatment of neuropathic pain. Basic-
Clin-Pharmacol-Toxicol. 2005; 96(6):399-409 
88. Vetulani J, Nalepa I. Antidepressants: past, present and 
future. Eur. J. Pharmacol. 2000; 405:351−363.  
89. Baldessarini JR. Drugs and treatment of psychiatric 
disorders (Depression and Mania). In: Goodman and Gilman’s 
The Pharmacological Basis of Therapeutics1996. 9
th edition. 
McGraw-Hill, New york. Chapter 19, p431. 
90. Shimizu M, Nishida A, Hayakawa H, Yamawaki S. Ca2+ 
release from inositol 1,4,5-trisphosphate-sensitive Ca2+ store 
by antidepressant drugs in cultured neurons of rat frontal 
cortex. J Neurochem. 1993; 60(2):595-601 
91. Takebayashi M, Kagaya A, Hayashi T, Motohashi N, 
Yamawaki S. gamma-Aminobutyric acid increases intracellular 
Ca2+ concentration in cultured cortical neurons: role of Cl- 
transport. Eur. J. Pharmacol. 1996; 297(1-2):137-43 
92. Yokogawa T, Kim SU, Krieger C, Puil E. Analysis of 
GABA(A)- and GABA(B)-receptor mediated effects on 
intracellular Ca(2+) in DRG hybrid neurones. Br. J. Pharmacol. 
2001; 134(1):98-107 
93. Hay DW, Wadsworth RM. The effects of calcium channel 
inhibitors on twitches and noradrenaline contractions of the rat 
bisected vas deferens. Eur. J. Pharmacol. 1983; 87(4):367-378 
94. Rego AC, Lambert JJ, Nicholls DG. Developmental 
profile of excitatory GABA(A) responses in cultured rat 
cerebellar granule cells. Neuroreport 2001; 12(3):477-482 
95. Nilsson M, Eriksson PS, Ronnback L, Hansson E. GABA 
induces Ca2+ transients in astrocytes. Neuroscience 1993; 
54(3):605-14 
96. Delpon E, Tamargo J, Sanchez Chapula J. Further 
characterization of the effects of imipramine on plateau 
membrane currents in guinea-pig ventricular myocytes.  
Naunyn Schmiedeberg's Archives of Pharmacology 1991; 
344(6):645-652. 
97.   Lee JB, Yoo KJ, Ha JH, Kwon OC, Lee KY, Kim WJ. 
Mechanism of inhibitory effect of imipramine on isolated rat 
detrusor muscle in relation to calcium modulation. Korean 
Journal of Pharmacology 1992; 28(1):81-89. 
98. Shim HS, Choi HC, Jeong YS, Kim JH, Lee KY, Sohn 
UD, et al. Effect of imipramine on calcium utilization of single 
cells isolated from canine detrusor. Korean Journal of 
Physiology and Pharmacology 1999; 3(4):439-445. 
Page 175